Nurix Therapeutics, Inc. (NRIX): Shareholders' Equity
$538.75M
As of 2025-11-30
$402.63M
As of 2026-05-31
+21.1%
3-year compound annual growth
+13.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $538.75M | +2.2% | 2026-01-28, Balance as of period end |
| 2024-11-30 | $526.99M | +162.8% | 2026-01-28, Balance as of period end |
| 2023-11-30 | $200.49M | -34.0% | 2026-01-28, Balance as of period end |
| 2022-11-30 | $303.70M | -11.3% | 2025-01-28, Balance as of period end |
| 2021-11-30 | $342.30M | +17.9% | 2023-02-09, Balance as of period end |
| 2020-11-30 | $290.27M | n/m | 2022-01-28, Balance as of period end |
| 2019-11-30 | -$57.71M | n/a | 2022-01-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $538.75M | +2.2% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $114.26M | -55.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $424.29M | -10.1% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $213.99M | -11.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$185.83M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$659.62M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $26.15M | +7.1% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $99.01M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $966.90M | -8.4% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗